BioTuesdays

Category - Markets

AIM ImmunoTech
Markets

Maxim ups AIM ImmunoTech PT to $5 from $2

Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five...

April 6, 2020
IDEAYA Biosciences Logo
Markets

HCW starts IDEAYA Biosciences at buy; PT $13

H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...

April 6, 2020
Imara
Markets

SVB Leerink starts Imara at OP; PT $25

SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...

April 6, 2020
Molecular Partners
Markets

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...

April 2, 2020
Chembio Diagnostics
Markets

Canaccord ups Chembio Diagnostics PT to $10 from $7

Canaccord Genuity raised its price target for Chembio Diagnostics (NASDAQ:CEMI) to $10 from $7, citing the launch of its 15-minute dual path platform (DPP) COVID-19 serology test in the U.S. The stock closed at $7.16 on...

April 2, 2020
Profound Medical Logo
Markets

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...

April 1, 2020
AVEO Pharmaceuticals Logo
Markets

HCW cuts AVEO Pharma PT to $4 from $6

H.C. Wainwright lowered its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $4 from $6, but reiterated a “buy” rating, citing discontinuation of the company’s ficlatuzumab program because of COVID-19 and reduced...

April 1, 2020
Aileron Therapeutics Logo
Markets

HCW halves Aileron Therapeutics PT to $3

H.C. Wainwright lowered its price target for Aileron Therapeutics (NASDAQ:ALRN) to $3 from $6, citing the removal of lead drug candidate, ALRN-6924, in combination with Ibrance in murine double minute 2 (MDM2) gene...

March 31, 2020